SummitTX Capital’s RAPT Therapeutics RAPT Stock Holding History

SummitTX Capital’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-91,912	Closed	-$2.37M	–	923
2025 Q3	$2.37M	Buy	+91,912	New	+$1.2M	0.1%	223

Other funds holding RAPT

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

SummitTX Capital's RAPT Position: Q4 2025 in Review

SummitTX Capital sold out of RAPT Therapeutics (RAPT) in Q4 2025, closing a stake of 91,912 shares — an estimated $2.37M sold.

SummitTX Capital first reported a position in RAPT in Q3 2025 and held it in 1 quarter. The position peaked at $2.37M in Q3 2025. 105 funds tracked by Wall St. Rank hold RAPT as of Q4 2025.

SummitTX Capital reported no remaining RAPT Therapeutics position as of Q4 2025 after selling out during the quarter.
SummitTX Capital sold 91,912 RAPT Therapeutics shares in Q4 2025, an estimated $2.37M.
SummitTX Capital first reported a position in RAPT Therapeutics in Q3 2025 and held it in 1 quarter.
SummitTX Capital's RAPT Therapeutics position peaked at $2.37M in Q3 2025.
105 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2025.

Based on SummitTX Capital's 13F filing for Q4 2025, filed 17 Feb 2026.